A case of metastatic lobular carcinoma with overexpression of Trop-2: Implications for the consideration of novel therapeutics

Breast Journal

Volumn 23, Issue 6, 2017, Pages 757-759

  Mojica, Wilfrido D ^a   Brandwein Weber, Margaret ^a   Korangy, Elizabeth A ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

antibody drug conjugate; breast cancer; invasive lobular carcinoma; Trop 2

Indexed keywords

CATENIN; CELL MEMBRANE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P120; TROP 2 PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN; CELL ADHESION MOLECULE; TACSTD2 PROTEIN, HUMAN; TUMOR ANTIGEN;

AGED; AXILLARY LYMPH NODE; BREAST BIOPSY; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER SURGERY; CANCER SURVIVAL; CASE REPORT; CLINICAL ARTICLE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; LOBULAR CARCINOMA; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; METASTATIC BREAST CANCER; NEEDLE BIOPSY; NOTE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SIMPLE MASTECTOMY; TUMOR BIOPSY; BREAST TUMOR; DIFFERENTIAL DIAGNOSIS; MASTECTOMY; METABOLISM; PATHOLOGY; SECONDARY;

AGED; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CARCINOMA, LOBULAR; CELL ADHESION MOLECULES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MASTECTOMY;

EID: 85029227629     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/tbj.12924     Document Type: Note

References (6)

1. Adachi Y, Ishiguro J, Kotani H, et al. Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive ductal carcinoma. BMC Cancer. 2016;16:248.
2. Alluri PG, Speers C, Chinnaiyan AM. Estrogen receptor mutations and their role in breast cancer progression. Breast Cancer Res. 2014;16:494.
3. Truin W, Voogd AC, Vreughenhil G, van der Sangen MJ, van Beek MW, Roumen RM. Influence of histology on the effectiveness of adjuvant chemotherapy in patients with hormone receptor positive invasive breast cancer. Breast. 2011;20:505-509.
4. Truin W, Voogd AC, Vreughenhil G, van der Heiden-vander Loo M, Siesling S, Roumen RM. Effect of adjuvant chemotherapy in postmenopausal patients with invasive ductal versus lobular breast cancer. Ann Oncol. 2012;23:2859-2865.
5. Amrogi F, Fornili M, Boracci P, et al. Trop-2 is a determinant of breast cancer survival. PLoS ONE. 2014;9:396993.
6. Bardia A, Mayer I, Diamond J, et al. Safety and tumor responses for the anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in refractory, metastatic, triple negative breast cancer (TNBC): an ongoing Phase II trial. In: Proceedings of the AACR-NCI-EROTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia, PA: AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr LB-16.